Lone Pine Capital’s Ascendis Pharma A/S ASND Stock Holding History

Lone Pine Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,436,981	Closed	-$229M	–	30
2021 Q3	$229M	Hold	1,436,981	–	–	0.77%	29
2021 Q2	$189M	Hold	1,436,981	–	–	0.61%	30
2021 Q1	$185M	Buy	1,436,981 +542,448	+61%	+$82.4M	0.67%	31
2020 Q4	$149M	Buy	+894,533	New	+$148M	0.54%	36

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Lone Pine Capital's ASND Position: Q4 2021 in Review

Lone Pine Capital sold out of Ascendis Pharma A/S (ASND) in Q4 2021, closing a stake of 1,436,981 shares — an estimated $229M sold.

Lone Pine Capital first reported a position in ASND in Q4 2020 and held it in 4 quarters. The position peaked at $229M in Q3 2021. 172 funds tracked by Wall St. Rank hold ASND as of Q4 2021.

Lone Pine Capital reported no remaining Ascendis Pharma A/S position as of Q4 2021 after selling out during the quarter.
Lone Pine Capital sold 1,436,981 Ascendis Pharma A/S shares in Q4 2021, an estimated $229M.
Lone Pine Capital first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 4 quarters.
Lone Pine Capital's Ascendis Pharma A/S position peaked at $229M in Q3 2021.
172 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2021.

Based on Lone Pine Capital's 13F filing for Q4 2021, filed 14 Feb 2022.